MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Vitae Pharmaceuticals Company Profile (NASDAQ:VTAE)

Consensus Ratings for Vitae Pharmaceuticals (NASDAQ:VTAE) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.00 (76.09% upside)

Analysts' Ratings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016WedbushReiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016JMP SecuritiesUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016Stifel NicolausUpgradeHold -> Buy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/10/2016Q1($0.51)($0.44)$0.05 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.33)($0.47)$0.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.33)($0.33)($0.33)
Q4 20161($0.33)($0.33)($0.33)
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)
Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateHeadline
06/30/16 03:12 PMVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -
06/30/16 09:52 AMVitae Pharmaceuticals, Inc. (VTAE) Updated Price Targets - FTSE News
06/29/16 09:52 AMCheck on Share Volatility: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily
06/29/16 09:52 AMVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Short Interest Decreased By 8.81% - Press Telegraph
06/29/16 09:52 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Company Rating and Target Watch - Telanagana Press
06/27/16 05:43 AMShare Update and Earnings Review for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph
06/26/16 05:53 AMHow Many Vitae Pharmaceuticals Inc (NASDAQ:VTAE)'s Analysts Are Bullish? - Press Telegraph
06/25/16 06:28 PMShare Volatility Check for: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph
06/24/16 09:48 AMCovering the Bases on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE): Where is the Stock Going? - Press Telegraph
06/24/16 09:48 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 09:48 AMDafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ... - Press Telegraph
06/24/16 09:48 AMVitae Pharmaceuticals, Inc. (VTAE) Current Analyst Ratings - Fiscal Standard
06/21/16 05:55 AMThis Weeks Broker Views For Vitae Pharmaceuticals, Inc. (VTAE) - Fiscal Standard
06/17/16 06:55 PMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Fell -2.14%: Cavium, Inc. (NASDAQ:CAVM), QLogic Corp. (NASDAQ ... - KC Register
06/17/16 06:55 PMVitae Pharmaceuticals (VTAE) Is Weak On High Volume Today - TheStreet.com
06/14/16 03:29 PMVitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference - [at noodls] - FORT WASHINGTON, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Richard Gregg, M.D., Chief Scientific Officer, ...
06/06/16 03:38 PMVitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer - [at noodls] - FORT WASHINGTON, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Carole Sable, M.D., has been named Chief ...
06/03/16 10:17 AMShare Rating Focus on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - HNN
06/02/16 07:46 PMStock in Overbought Territory: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - HNN - Stock in Overbought Territory: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)HNNShares of Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) have entered overbought territory as the 14-day RSI reading touched 80.45 after yesterday's close. Investors should be cautious of taking positions as this might indicate the stock is due to reverse ...
06/02/16 10:31 AMTarget Price and Stock Performance Rundown for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - HNN - Target Price and Stock Performance Rundown for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)HNNDuring the latest trading session, Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) shares traded +6.28%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
05/30/16 10:30 PMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Daily Sentiment Score Of 0.435 - Stocks Daily - Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Daily Sentiment Score Of 0.435Stocks DailyVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) has a daily sentiment score of 0.435. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web. The ...and more »
05/30/16 10:30 PMNext Weeks Broker Price Targets For Vitae Pharmaceuticals, Inc. (VTAE) - Share Trading News - Next Weeks Broker Price Targets For Vitae Pharmaceuticals, Inc. (VTAE)Share Trading News04/11/2016 – BMO Capital Markets began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 15 price target on the stock. 03/17/2016 – Vitae Pharmaceuticals, Inc. was upgraded to “mkt outperform” ...Vitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Shorted Shares Increased By 7.08%HNNall 4 news articles »
05/28/16 09:40 AMDafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ... - CCH Daily News - Dafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ...CCH Daily NewsNathan Fischel increased its stake in Vitae Pharmaceuticals Inc (NASDAQ:VTAE) by 307.49% based on its latest 2016Q1 regulatory filing with the SEC. Dafna Capital Management Llc bought 594,149 shares as the company's stock declined 61.65% while ...
05/27/16 10:45 AMStock Rating Review for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Wall Street Hints and News - Stock Rating Review for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE). Covering ...Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Tracking Stock Rating and Target ProjectionsThe PostHold Calls Count For Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) At 0Vanguard Tribuneall 653 news articles »
05/27/16 10:45 AMLatest Analyst Ratings For Vitae Pharmaceuticals, Inc. (VTAE) - Share Trading News - Latest Analyst Ratings For Vitae Pharmaceuticals, Inc. (VTAE)Share Trading News04/11/2016 – BMO Capital Markets began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 15 price target on the stock. 03/17/2016 – Vitae Pharmaceuticals, Inc. was upgraded to “mkt outperform” ...and more »
05/26/16 03:32 PMVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/26/16 05:22 AMTarget Check and Stock Performance Recap Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Wall Street Hints and News - Target Check and Stock Performance Recap Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Vitae Pharmaceuticals, Inc.and more »
05/25/16 05:44 PMThe 3 Best Developmental Stage Biotech Stocks Surging Now -
05/23/16 04:47 PMETF’s with exposure to Vitae Pharmaceuticals, Inc. : May 23, 2016 -
05/20/16 09:46 AMVitae Pharmaceuticals, Inc. :VTAE-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 04:22 PMVitae Pharmaceuticals reports 1Q loss -
05/10/16 03:08 PMVitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results - [at noodls] - Proof-of-concept data for VTP-38543 expected in the second half of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. ...
05/10/16 06:07 AMQ1 2016 Vitae Pharmaceuticals Inc Earnings Release - After Market Close -
05/09/16 03:58 PMVitae Pharmaceuticals to Present at IMMUNOLOGY 2016 - [at noodls] - Poster to highlight positive Phase 1 data for RORγt inhibitor VTP-43742 FORT WASHINGTON, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology ...
03/17/16 10:45 AMVitae Pharmaceuticals Inc (VTAE) Stock Skyrockets on Promising Psoriasis Drug - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Vitae Pharma saw its stock skyrocket on Thursday on positive phase 2a clinical trial results from its new psoriatic drug.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/03/vitae-pharma-vtae-stock/">Vitae Pharmaceuticals Inc (VTAE) Stock Skyrockets on Promising Psoriasis Drug</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
03/16/16 04:18 PMUPDATE 1-Vitae Pharma's psoriasis drug succeeds in mid-stage study - March 16 (Reuters) - Drug developer Vitae Pharmaceuticals Inc said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up...
03/14/16 01:11 PMRevenue Update on Vitae Pharmaceuticals Inc(NASDAQ:VTAE) - Street Edition - Revenue Update on Vitae Pharmaceuticals Inc(NASDAQ:VTAE)Street EditionVitae Pharmaceuticals Inc(NASDAQ:VTAE) announced the earnings results for Fiscal Year 2015 and Q4. The results came in during After-hours on Mar 3, 2016. Company reported revenue of $92.09K. Analysts estimated a revenue of $120.00K. Earnings per ...Vitae Pharmaceuticals (NASDAQ:VTAE) Institutional Investors Sentiment Increased in 2015 Q3Clinton Financialall 2 news articles »
03/14/16 09:58 AMVitae Pharmaceuticals, Inc. :VTAE-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/14/16 06:05 AM7 Breakout Stocks Spiking on Big Volume -
03/10/16 12:04 PMVITAE PHARMACEUTICALS, INC Financials -
03/04/16 04:43 PMVITAE PHARMACEUTICALS, INC Files SEC form 10-K, Annual Report -
03/04/16 08:59 AMVitae (VTAE) Stock Plunges on Q4 Loss -
03/04/16 08:35 AMEdited Transcript of VTAE earnings conference call or presentation 3-Mar-16 9:30pm GMT -
03/04/16 06:39 AMVitae Pharmaceuticals downgraded by Stifel -
03/03/16 04:02 PMVitae Pharmaceuticals reports 4Q loss -
03/03/16 03:30 PMVitae Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today -
03/03/16 03:12 PMVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
02/26/16 10:55 AMCould Vitae Pharmaceuticals Inc Decline After Today's Huge Increase? - Franklin Independent - Could Vitae Pharmaceuticals Inc Decline After Today's Huge Increase?Franklin IndependentThe stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) is a huge mover today! The stock increased 5.81% or $0.52 during the last trading session, hitting $9.47. About 133,655 shares traded hands or 3.08% up from the average. Vitae Pharmaceuticals Inc ...
02/26/16 10:55 AMVitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on March 3, 2 - FORT WASHINGTON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, March 3, 2016 at 4:30 p.m. EST to discuss fourth quarter and full year 2015 ...
02/25/16 03:30 PMVitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016 - [GlobeNewswire] - FORT WASHINGTON, Pa., Feb. 25, 2016-- Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company, will host a conference call on Thursday, March 3, 2016 at 4:30 p.m. EST to discuss fourth quarter ...
About Vitae Pharmaceuticals

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTAE
  • CUSIP:
Key Metrics:
  • Previous Close: $10.79
  • 50 Day Moving Average: $9.50
  • 200 Day Moving Average: $9.51
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $311.19M
  • Current Quarter EPS Consensus Estimate: $-1.74 EPS
Additional Links:
Vitae Pharmaceuticals (NASDAQ:VTAE) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha